Andersen-Tawil syndrome treatment sales will grow through 2036, led by Type 2 at 62.5% of the disease type segment in 2026. Beta-blockers lead the drug class segment with a 34.8% share. The market is projected to reach USD 2.4 billion in 2026 and USD 5.07 billion by 2036.